Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma

Figure 2 Kaplan-Meier plot of progression-free survival and overall survival since commencement of hepatic arterial infusion chemotherapy according to neutrophil to lymphocyte ratio[31]. A: Median progression-free survival of the patients with high neutrophil to lymphocyte ratio (NLR) was 3.2 months, which was significantly worse than that of the patients with low NLR, 5.6 months (P < 0.01); B: Median overall survival of the patients with high NLR was 8.0 months, which was significantly worse than that of the patients with low NLR, 20.7 months (P < 0.01). Image, High NLR; image, Low NLR. Citation: Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, Kitamura K, Kagaya T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res 2015; 45: 949-959. Copyright © 2014. Published by John Wiley and Sons. The authors have obtained the permission for figure using (Supplementary material).